DailyIQ
Last updated1 minute ago

AMGN·Amgen Inc.

$402.73
-0.25 (-0.06%)
Overnight$401.53-1.20 (-0.30%)
High
$410.81
Open
$402.86
Market Cap
216.69B
52W High
$447.03
Low
$396.01
P. Close
$402.73
P/E
24.78
52W Low
$287.25
Fwd P/E
16.47
DailyIQ Est.
$395.89
Inst. Ownership
44.6%
Short Interest
2.61%
Days to Cover
4.9
Technical Score (1D)
73
BULLISH
News Sentiment
50
MIXED
On Oct 6, Amgen Inc. was highlighted on Zacks.com as one of the most searched stocks, indicating significant investor interest. On Oct 6, the company's shares had fallen 7.8% over the past month, outpacing the modest gain of the broader S&P 500 composite. On Oct 6, the biomedical and genetics sector had declined 6.7% during the same period. On Oct 6, the article noted that while media releases or rumors can spark short‑term price movements, long‑term valuation hinges on earnings projections and fundamental factors. On Oct 6, the article emphasized that Amgen's performance was notable relative to its sector and the broader market. On Oct 6, the article underscored that Amgen's ranking among Zacks’ most searched stocks reflected heightened attention from investors.
LOW TARGET
$225 -44.0%
3 analysts
MEAN TARGET
$391 -2.6%
28 analysts
HIGH TARGET
$500 +24.5%
12 analysts
PRICE RANGE
$225.00 - $500.00
SB / B / H / S / SS
6/14/20/2/1
DAILYIQ EST.
$395.89 (-1.4%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NMS
Country
United States
Website
Symbol
AMGN
Description
Amgen Inc. is a global biotechnology company focused on the discovery, development, manufacturing, and delivery of human therapeutics. The company's core value proposition lies in its diverse portfolio of innovative medicines designed to treat a wide range of serious illnesses. Key therapeutic areas include immunology, oncology, cardiovascular disease, bone health, and nephrology, with flagship products such as Enbrel, Repatha, and Prolia. Amgen distributes its products through healthcare providers, pharmacies, and direct-to-consumer channels, establishing a broad market reach. Strategic collaborations with other pharmaceutical companies, such as AstraZeneca and Novartis, further enhance its product pipeline and market presence, solidifying its competitive position in the biotechnology landscape.
Bought (1Y)
0 shares
$0
Sold (1Y)
10,112 shares
$4.1M
Khosla RachnaSVP, Business Development
Option Exercise1,252 shares2026-08-13
Khosla RachnaSVP, Business Development
Sell1,252 shares2026-08-13
Khosla RachnaSVP, Business Development
Option Exercise1,252 shares2026-08-13
Khosla RachnaSVP, Business Development
Sell2,000 shares2026-08-11
Busch Matthew C.VP, Finance & CAO
Award/Grant730 shares2026-08-07
69/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
67.2%
Net Margin
21.0%
Revenue CAGR
5.2%
Current Ratio
1.14x
Debt / Equity
6.31x
Return on Equity
89.1%
Earnings Summary
Amgen Inc. is a global biotechnology firm that discovers, develops, manufactures, and delivers human therapeutics across immunology, oncology, cardiovascular disease, bone health, and nephrology, with flagship products such as Enbrel, Repatha, and Prolia, positioning it as a key player in the drug manufacturers sector. In the most recent two quarters, Amgen posted EPS of $5.31 in Q4 2024 and $4.90 in Q1 2025, both beating estimates of $5.08 and $4.26 respectively, while revenue rose to $9.09 billion and $8.15 billion, respectively, reflecting a modest decline in revenue growth from the prior year’s $9.18 billion and $9.18 billion; EPS growth accelerated from $6.02 in Q2 2025 to $5.64 in Q3 2025, with revenue increasing to $9.56 billion, indicating a rebound in top‑line momentum. Historically, Amgen has maintained a steady YoY revenue growth trajectory, with EPS consistently beating analyst estimates in the last four quarters, underscoring robust profitability despite occasional revenue deceleration; the company’s ability to sustain earnings growth even when revenue growth slows has been a recurring pattern. Recent news highlights a global rollout of Veeva Systems’ Vault CRM to streamline commercial operations and a FDA approval that shortens monitoring for Imdelltra, both developments poised to enhance sales efficiency and broaden patient access, potentially supporting future revenue gains.

EPS

EstBeatMiss
$4.54$5.03$5.53$6.02$6.52Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$5.78 - -
Q2'26$5.73$6.29+9.8%
Q1'26$4.77$5.15+8.0%
Q4'25$4.83$5.29+9.6%
Q3'25$5.01$5.64+12.5%
Q2'25$5.28$6.02+14.1%

Revenue

EstBeatMiss
$8.3B$8.9B$9.4B$10.0B$10.5BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$10.2B - -
Q2'26$9.6B$10.1B+4.6%
Q1'26$8.6B$8.6B+0.5%
Q4'25$9.7B$9.9B+2.1%
Q3'25 - $9.6B -
Q2'25 - $9.2B -

Market Data

AMGN Stock Snapshot

BULLISH73/100
$401.53−$1.20 (0.3%)
Market cap
216.69B
P/E ratio
24.8
Day range
$396.01 – $410.81
News sentiment
50/100 · Neutral
Analyst target
$390.94 (-2.6%)
Consensus
Hold · 43 analysts
52-week range+39.8% off low · -10.2% from high
$287.25$447.03
Price $401.53 DailyIQ Est. $395.89

The setup on Amgen Inc. is the constructive kind - confirmation across timeframes, not one lone indicator. A stock this widely held moves on consensus revisions more than on individual catalysts.

Reverse DCF

What growth is priced into AMGN?

RICH

At today's price, Amgen Inc. needs to grow free cash flow about 13.8% a year for the next 10 years to justify its valuation at a 7.58% cost of capital. Over its actual history it has compounded free cash flow at 4.3% a year, so the market is asking for 9.5 percentage points above its own delivered rate. On that basis AMGN looks priced above what its own growth record supports.

Implied FCF growth
13.8%
Historical FCF CAGR
4.3%
Growth gap
+9.5 pts
Verdict
RICH
Discount rate (WACC)
7.58%
Beta
0.62

Behaviour On Record

What AMGN's own history says about today's numbers

Realized volatility (21d)
38.9% 95th pct
Below its peak
-9.3%
vs 200-day average
+10.6%
Up days (1y)
52%

Amgen Inc. is currently running 38.9% annualised volatility over the last 21 sessions. Measured against AMGN's own 13 years of daily returns rather than a market-wide average, that is the 95th percentile — an extreme by its own standards, against a typical reading of 22.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

AMGN is trading -9.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -21.4%, and the deepest was -26.3% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +10.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 80th percentile — a wider gap than this stock usually carries. Over the past year AMGN closed higher on 52% of sessions, and it is currently 4 sessions into a falling streak.

On October specifically: over 13 years of records, AMGN finished the month higher 5 of 13 times, with a median return of -0.7% and an average of +0.8%. Its strongest month historically has been July at +3.9% on average, its weakest September at -1.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: AMGN has opened more than 2% away from the prior close in 44 of 3,265 sessions (1.3% of the time), with the largest gaps running +5.4% and -9.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, AMGN moved an average of 5.2% in the session after earnings, closing higher 2 of those 3 times, with a median move of +4.9% and a largest of +6.9%.

All figures computed from 3,266 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against AMGN's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of AMGN's sector?

Amgen Inc. sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#8 of 12
Sector state
Lagging
Sector rotation score
0

Options Market

What is the options market pricing for AMGN?

CallsPuts

For Amgen Inc.'s nearest expiry (2026-10-16, 9 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.50), with at-the-money implied volatility around 0.8%. The options market is pricing roughly a ±0.1% move by that expiry — a range of about $403.50–$404.50.

Put/call ratio (2026-10-16)
0.50
ATM implied volatility
0.8%
Total open interest
3
Expected move by 2026-10-16
±0.1% ($403.50–$404.50)

Analyst Rating Changes

Are analysts turning bullish or bearish on AMGN?

Scotiabank most recently reiterated its rating on Amgen Inc. to Sector Outperform on Sep 29, 2026 with a price target of $500 (from $450). Over the last 90 days, coverage has run 0 upgrades against 2 downgrades, a net bearish lean.

Latest action
Scotiabank — Sector Outperform
90-day upgrades
0
90-day downgrades
2
Net rating momentum
-2
DateFirmActionRatingPrice target
Sep 29, 2026ScotiabankMaintainedSector Outperform$450 → $500
Sep 10, 2026HSBCDowngradeBuy → Hold$445 → $425
Sep 8, 2026BMO CapitalDowngradeOutperform → Market Perform$450
Sep 8, 2026Cantor FitzgeraldReiteratedNeutral$400
Sep 4, 2026Wells FargoMaintainedEqual-Weight$400 → $435
Aug 20, 2026Piper SandlerMaintainedOverweight$427 → $457
Aug 19, 2026Morgan StanleyMaintainedEqual-Weight$351 → $362
Aug 19, 2026Argus ResearchMaintainedBuy$375 → $460
Aug 18, 2026MizuhoMaintainedNeutral$303 → $352
Aug 18, 2026Cantor FitzgeraldMaintainedNeutral$350 → $400
Aug 14, 2026BarclaysMaintainedEqual-Weight$360 → $380
Aug 10, 2026GuggenheimMaintainedNeutral$343 → $388

AMGN Competitive Positioning

Amgen Inc. (AMGN) is tracked alongside these names in Drug Manufacturers - General on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

50/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Amgen (AMGN) has been highlighted on Zacks.com as one of the most searched stocks, drawing investor interest. The company’s shares fell 7.8% over the past month, outpacing the broader S&P 500 composite’s modest gain. The biomedical and genetics sector, to which Amgen belongs, declined 6.7% during the same period. The article notes that while media releases or rumors can spark short‑term price movements, long‑term valuation hinges on earnings projections and fundamental factors.
What did this article say?
On September 22, 2026, Ohio Representative David Taylor purchased shares of Amgen, with the transaction valued between $3,003 and $45,000. The filing, reported on October 1, 2026, indicates a significant insider acquisition of the company’s stock. Such a purchase by a public official can be interpreted as a vote of confidence in Amgen’s prospects and may influence investor sentiment. The transaction size, while notable, does not represent a large block that would materially shift the company’s share price. Nonetheless, it adds to the narrative of positive insider activity for Amgen.
What did this article say?
A global market study projected the recombinant protein sector to grow to $5.8 billion by 2030, citing rising demand for biologics and advances in AI‑driven protein design. Amgen was listed among leading companies such as Thermo Fisher, Merck, Bio‑Techne and GenScript in the benchmark analysis. The report highlighted tariff disruptions as a potential risk but overall growth outlook remained positive. The inclusion signals continued relevance of Amgen’s protein platform in a expanding therapeutic landscape. No immediate financial guidance or operational changes were disclosed.
What did this article say?
Scotiabank analyst Louise Chen upgraded Amgen to a Sector Outperform rating on September 29, citing strong pipeline prospects and solid financials. The bank increased its price target from $450 to $500, reflecting confidence in the company’s growth trajectory. This upgrade signals a positive outlook for investors and may support upward pressure on the stock.
What did this article say?
On September 22, Amgen Inc. announced that its Phase 3 trial of dazodalibep for systemic Sjögren’s disease met its primary endpoint, showing statistically significant and clinically meaningful improvements in disease activity. The data were viewed as a de‑risking milestone for the drug, though full data were not yet released. Citi maintained a neutral rating and a $405 price target, noting that the magnitude of efficacy and competitive positioning remain uncertain until more details emerge.
What did this article say?
Amgen released positive topline data from its Phase 3 OASIZ 301 trial of dazodalibep in Sjögren’s disease, sparking renewed interest in the company’s autoimmune portfolio. The announcement coincided with a 15.5% rise in share price over the past 90 days and a 27.6% year‑to‑date gain. Investors view the results as a catalyst for long‑term growth potential in the autoimmune segment.
What did this article say?
Amgen Inc. (NASDAQ:AMGN) announced that its experimental drug dazodalibep achieved the primary endpoint in a late‑stage trial for Sjögren’s disease. After 48 weeks, patients with moderate‑to‑severe disease activity experienced statistically significant and clinically meaningful improvements, with most adverse events being mild or moderate. The study represents a potential new growth avenue for Amgen in the autoimmune space, although the drug remains several steps from commercialization. The result strengthens Amgen’s pipeline amid competitive and patent pressures on its established products.

Technical Analysis

Real-time indicators across multiple timeframes

73
BULLISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $84.33B combined position · 14 adding, 9 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy54,838,82610.16%$17.95B2026-01-29
BlackRock, Inc.▲ Buy49,362,0169.15%$17.87B2026-08-07
Capital World Investors▼ Sell29,075,3295.39%$10.53B2026-08-12
Invesco Ltd.▲ Buy16,320,4463.02%$5.91B2026-08-14
Geode Capital Management, LLC▲ Buy15,696,0682.91%$5.67B2026-08-12
Morgan Stanley▼ Sell13,653,6922.53%$4.94B2026-08-13
Wells Fargo & Company▲ Buy7,237,5621.34%$2.62B2026-08-14
Capital Research Global Investors▼ Sell6,272,6251.16%$2.27B2026-08-12
Northern Trust Corp▼ Sell6,200,9941.15%$2.25B2026-08-13
Norges Bank▼ Sell5,625,5841.04%$2.04B2026-08-12
Bank of America Corp▼ Sell5,058,8300.94%$1.83B2026-08-14
Goldman Sachs Group Inc▲ Buy4,559,3320.84%$1.65B2026-08-14
JPMorgan Chase & Co▼ Sell3,971,1840.74%$1.43B2026-08-12
FMR LLC (Fidelity)▼ Sell3,491,8220.65%$1.26B2026-08-13
Susquehanna International Group, LLP▲ Buy3,239,7750.60%$1.17B2026-08-14
Wellington Management Group LLP▲ Buy2,742,2710.51%$993.03M2026-08-14
Citadel Advisors LLC• Hold2,469,3840.46%$894.21M2026-09-02
Fisher Asset Management, LLC▲ Buy1,589,5540.29%$575.61M2026-08-04
Citigroup Inc▲ Buy1,424,4690.26%$515.83M2026-08-03
D. E. Shaw & Co., Inc.▲ Buy1,379,5170.26%$499.55M2026-08-14
Two Sigma Investments, LP▲ Buy1,130,3810.21%$409.33M2026-08-14
Janus Henderson Group plc• Hold1,107,1590.21%$389.51M2026-05-18
Neuberger Berman Group LLC▲ Buy646,7980.12%$234.17M2026-08-13
Prudential Financial Inc▲ Buy578,4740.11%$209.48M2026-08-12
AllianceBernstein L.P.▼ Sell587,2700.11%$206.63M2026-08-14
Q2 2026 flow:14.18M sh bought ($5.14B)7.91M sh sold ($2.86B)net +6.27M sh (+$2.28B)
Congressional Trading Activity
25 disclosed trades · ~$371.5K est. traded value · 13 buys, 12 sells
MemberChamberStateTypeAmountTradedFiled
David J. TaylorHouseOH02▲ Buy$1K - $15K2026-09-222026-10-01
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-08-262026-09-05
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2026-08-122026-09-02
David J. TaylorHouseOH02▲ Buy$1K - $15K2026-06-052026-06-12
Maria Elvira SalazarHouseFL27▼ Sell$15K - $50K2026-04-172026-05-08
Alan ArmstrongSenateOK▼ Sell$15K - $50K2026-03-272026-07-21
Maria Elvira SalazarHouseFL27▲ Buy$15K - $50K2026-03-242026-04-21
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-02-262026-03-06
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-01-292026-02-02
David J. TaylorHouseOH02▲ Buy$1K - $15K2026-01-162026-02-02
David J. TaylorHouseOH02▼ Sell$1K - $15K2025-12-032025-12-05
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-10-242025-10-28
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-09-252025-10-22
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-09-112025-09-27
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2025-09-042025-10-03
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-242025-08-13
Cliff BentzHouseOR02▲ Buy$1K - $15K2025-06-062025-07-09
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-05-142025-05-19
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-05-052025-05-06
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2025-04-162025-05-09
Tommy TubervilleSenateAL▼ Sell$15K - $50K2025-04-152026-08-05
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-04-112025-05-08
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-02-242025-03-09